Efficacy News and Research

RSS

WIN Consortium proposes unique alliance to fight cancer

WIN Consortium proposes a unique alliance to fight cancer and invites you to join the 3rd annual symposium: Gateways to efficacy of cancer diagnostics and therapeutics to be held on 6th to 8th of July at the Palais des Congrès in Paris, France.

10 Feb 2011

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.

10 Feb 2011

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, its nasal aerosol corticosteroid in development for the treatment of perennial allergic rhinitis (PAR) and seasonal allergic rhinitis (SAR).

10 Feb 2011

New study: Fetal surgery for spina bifida greatly improves child's mobility

Performing delicate surgery in the womb, months before birth, can substantially improve outcomes for children with a common, disabling birth defect of the spine. Experts at The Children's Hospital of Philadelphia co-led a new landmark study showing that fetal surgery for spina bifida greatly reduces the need to divert fluid from the brain, improves mobility and improves the chances that a child will be able to walk independently.

9 Feb 2011

Evotec signs definitive agreement to acquire all shares in Kinaxo

Evotec AG today announced the signing of a definitive agreement to acquire all shares in Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs.

9 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

QLT Inc. today announced results from a Phase II proof-of-concept clinical trial for the olopatadine punctal plug delivery system (O‑PPDS).

9 Feb 2011

Research findings highlight potential for noninvasive MSC delivery to treat Parkinson disease

Successful intranasal delivery of stem cells to the brains of rats with Parkinson disease yielded significant improvement in motor function and reversed the dopamine deficiency characteristic of the disease.

9 Feb 2011

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.

9 Feb 2011

Karo Bio fourth quarter net loss increases to MSEK 50.1

The January - December period and fourth quarter 2010 in brief

9 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

ACE: Hula hooping workouts offer substantial and positive results

The American Council on Exercise, America's leading authority on fitness and the largest nonprofit fitness certification, education and training organization in the world, today announced exclusive study findings that conclude hula hooping workouts offer substantial and positive results.

9 Feb 2011

Novel technique could speed up the development of peptide-based drugs against cancer

Researchers at the University at Buffalo have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes.

9 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

NMS Labs launches unique test for Methotrexate

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy and helping physicians with therapeutic drug monitoring of patients for the therapeutic agent, Methotrexate.

8 Feb 2011

ASBP concerned over FDA rejection of Contrave drug

The American Society of Bariatric Physicians is concerned that the FDA recently rejected the weight-loss drug Contrave, contradicting the FDA advisory panel's recommendation for approval. The rejection of Contrave marks the third weight-loss drug to be rejected by the FDA in the past six months.

8 Feb 2011

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

8 Feb 2011

Reducing the cardiovascular disease gender gap

The European Society of Cardiology (ESC) is working with the National Cardiac Societies of its 53 member countries on a project to raise awareness of the disturbing gender gap in cardiovascular disease (CVD). In partnership with the European Heart Network (EHN) and the World Heart Federation (WHF), the ESC has developed the Women@Heart contest in which national societies submit ideas for public awareness campaigns aimed at informing both health professionals and women of the dangers of complacency about CVD.

8 Feb 2011

Total flu cover with one shot

In a medical breakthrough, English scientists have developed a so-called “universal” vaccine to influenza - one that protects against all strains of the potentially deadly illness. This would do away with the need for a new vaccine each flu season they say. Seasonal flu affects up to 20 percent of the population and kills an average of 24,600 people each year. This vaccine would act against swine flu as well assure researchers.

8 Feb 2011

Efficacy News and Research

WIN Consortium proposes unique alliance to fight cancer

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Teva reports positive results from QNAZE Phase III perennial allergic rhinitis trial

New study: Fetal surgery for spina bifida greatly improves child's mobility

Evotec signs definitive agreement to acquire all shares in Kinaxo

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

Repligen third quarter total revenue increases 26% to $7,068,000

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

Research findings highlight potential for noninvasive MSC delivery to treat Parkinson disease

Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey

Karo Bio fourth quarter net loss increases to MSEK 50.1

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

ACE: Hula hooping workouts offer substantial and positive results

Novel technique could speed up the development of peptide-based drugs against cancer

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

NMS Labs launches unique test for Methotrexate

ASBP concerned over FDA rejection of Contrave drug

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Reducing the cardiovascular disease gender gap

Total flu cover with one shot

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News